{"entity":{"id":"nct05963490","kind":"trial","name":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","aka":["SLOT"],"tldr":"A phase 2 trial of regorafenib and toripalimab in colorectal cancer, run by Fudan University, now recruiting.","summary":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT05963490 by Fudan University, with a registry enrolment figure of 108 participants, started 2023-04-25 and due to reach its primary completion in 2025-04-25. Interventions recorded: Regorafenib; Toripalimab; Radiotherapy; Regorafenib. Conditions listed: Microsatellite Stable Metastatic Colorectal Cancer. Primary outcome: OS. Colorectal eligibility wording from the registry: \"Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05963490","url":"https://clinicaltrials.gov/study/NCT05963490"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","checkpoint-inhibitor","imrt-igrt","kinase-inhibitors"],"targets":[],"drugs":["regorafenib","toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05963490","phase":"2","setting":"A Prospective, Randomized, Controlled Phase II Trial of Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab as Third-line Treatment in Patients With Metastatic Colorectal Cancer","sponsor":"Fudan University","enrolled":108,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05963490/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}